Last updated on January 2020

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors


Brief description of study

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned to continue with their regular medication. In addition, the study will assess safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Clinical Study Identifier: NCT03417245

Find a site near you

Start Over

Investigational Site Number 122

Chapel Hill, NC United States
  Connect »

Investigational Site Number 104

Philadelphia, PA United States
  Connect »

Investigational Site Number 701

St. Petersburg, Russian Federation
  Connect »